August 29, 2022 Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology Read press release
August 17, 2022 An impact company committed to improving the health of patients worldwide, MedinCell publishes its 2021-2022 ESG annual report Read press release
July 29, 2022 MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report Read press release
July 28, 2022 MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000 Read press release
